United States Biotechnology & Medical Research

ACELYRIN Inc (SLRN)

Track

Track

Ticker: SLRN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for ACELYRIN Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Kim Mina Chief Executive Officer Executive Director
Transaction date
Sale
Price
63.31
Quantity 3,957 +38.9%
Value US$2,712,958
4.0
Murugan Amar Chief Legal Officer Officer
Transaction date
Sale
Price
80.93
Quantity 12,607 -29.7%
Value US$566,420
Mpofu Shephard Chief Medical Officer Officer
Transaction date
Sale
Price
108.83
Quantity 43,183 -29.8%
Value US$4,475,004
Kim Mina Officer; Director Executive Director
Transaction date
Proposed sale
Price
2.75
Quantity 18,052
Value US$49,643
3.2
Becker Daniel J. Non-Executive Director
Transaction date
Sale
Price
6.86
Quantity 1 -0.0%
Value US$7
3.1
Lin Shao-Lee Chief Executive Officer Executive Director
Transaction date
Sale
Price
6.63
Quantity 9,961 -0.6%
Value US$66,024
Peloso Paul Former Affiliate
Transaction date
Proposed sale
Price
8.38
Quantity 56,129
Value US$470,361
3.1
Lin Shao-Lee Chief Executive Officer Executive Director
Transaction date
Sale
Price
7.60
Quantity 15,701 -1.0%
Value US$119,403
3.1
Lin Shao-Lee Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
7.41
Quantity 10,691 -0.7%
Value US$79,188
3.2
Becker Daniel J. Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 3,000 +inf%
Value US$54,000
2.4
Dier Mardi CFO and CBO Officer
Transaction date
Purchase
Price
18.00
Quantity 875 +inf%
Value US$15,750
2.4
Dier Mardi CFO and CBO Officer
Transaction date
Purchase
Price
18.00
Quantity 875 +inf%
Value US$15,750
2.4
Dier Mardi CFO and CBO Officer
Transaction date
Purchase
Price
18.00
Quantity 5,556 +inf%
Value US$100,008
2.9
Svoronos Dawn Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 15,000 +inf%
Value US$270,000
3.2
Gosebruch Henry O Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 50,000 +inf%
Value US$900,000
Oyston Ronald Chief People Officer Officer
Transaction date
Purchase
Price
18.00
Quantity 26 +inf%
Value US$468
Oyston Ronald Chief People Officer Officer
Transaction date
Purchase
Price
18.00
Quantity 1,000 +inf%
Value US$18,000
Kim Mina Chief Legal & Admin. Officer Officer
Transaction date
Purchase
Price
18.00
Quantity 5,000 +inf%
Value US$90,000
Peloso Paul Chief Medical Officer Officer
Transaction date
Purchase
Price
18.00
Quantity 6,000 +inf%
Value US$108,000
3.7
SEIDENBERG BETH C Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 60,000 +inf%
Value US$1,080,000
3.7
SEIDENBERG BETH C Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 1,250,000 +14.6%
Value US$22,500,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-03-19 2025-03-17 S Sale
Kim Mina

Chief Executive Officer

Executive Director
3,957 +38.9%
63.31
US$2,712,958 		3,957 +38.9% 63.31 US$2,712,958
2025-03-19 2025-03-17 S Sale
4.0
Murugan Amar

Chief Legal Officer

Officer
12,607 -29.7%
80.93
US$566,420 		12,607 -29.7% 80.93 US$566,420
2025-03-19 2025-03-17 S Sale
Mpofu Shephard

Chief Medical Officer

Officer
43,183 -29.8%
108.83
US$4,475,004 		43,183 -29.8% 108.83 US$4,475,004
2025-03-14 2025-03-17 PrS Proposed sale
Kim Mina

Officer; Director

Executive Director
18,052
2.75
US$49,643 		18,052 2.75 US$49,643
2024-07-19 2024-07-17 S Sale
3.2
Becker Daniel J.
Non-Executive Director
1 -0.0%
6.86
US$7 		1 -0.0% 6.86 US$7
2024-04-03 2024-04-01 S Sale
3.1
Lin Shao-Lee

Chief Executive Officer

Executive Director
9,961 -0.6%
6.63
US$66,024 		9,961 -0.6% 6.63 US$66,024
2024-03-20 2024-03-20 PrS Proposed sale
Peloso Paul

Former Affiliate
56,129
8.38
US$470,361 		56,129 8.38 US$470,361
2024-02-22 2024-02-20 S Sale
3.1
Lin Shao-Lee

Chief Executive Officer

Executive Director
15,701 -1.0%
7.60
US$119,403 		15,701 -1.0% 7.60 US$119,403
2024-01-04 2024-01-02 PlS Planned sale
3.1
Lin Shao-Lee

Chief Executive Officer

Executive Director
10,691 -0.7%
7.41
US$79,188 		10,691 -0.7% 7.41 US$79,188
2023-05-11 2023-05-09 B Purchase
3.2
Becker Daniel J.
Non-Executive Director
3,000 +inf%
18.00
US$54,000 		3,000 +inf% 18.00 US$54,000
2023-05-11 2023-05-09 B Purchase
2.4
Dier Mardi

CFO and CBO

Officer
875 +inf%
18.00
US$15,750 		875 +inf% 18.00 US$15,750
2023-05-11 2023-05-09 B Purchase
2.4
Dier Mardi

CFO and CBO

Officer
875 +inf%
18.00
US$15,750 		875 +inf% 18.00 US$15,750
2023-05-11 2023-05-09 B Purchase
2.4
Dier Mardi

CFO and CBO

Officer
5,556 +inf%
18.00
US$100,008 		5,556 +inf% 18.00 US$100,008
2023-05-11 2023-05-09 B Purchase
2.9
Svoronos Dawn
Non-Executive Director
15,000 +inf%
18.00
US$270,000 		15,000 +inf% 18.00 US$270,000
2023-05-11 2023-05-09 B Purchase
3.2
Gosebruch Henry O
Non-Executive Director
50,000 +inf%
18.00
US$900,000 		50,000 +inf% 18.00 US$900,000
2023-05-11 2023-05-09 B Purchase
Oyston Ronald

Chief People Officer

Officer
26 +inf%
18.00
US$468 		26 +inf% 18.00 US$468
2023-05-11 2023-05-09 B Purchase
Oyston Ronald

Chief People Officer

Officer
1,000 +inf%
18.00
US$18,000 		1,000 +inf% 18.00 US$18,000
2023-05-11 2023-05-09 B Purchase
Kim Mina

Chief Legal & Admin. Officer

Officer
5,000 +inf%
18.00
US$90,000 		5,000 +inf% 18.00 US$90,000
2023-05-11 2023-05-09 B Purchase
Westlake BioPartners Fund II, L.P.
Large shareholder
1,250,000 +14.6%
18.00
US$22,500,000 		1,250,000 +14.6% 18.00 US$22,500,000
2023-05-11 2023-05-09 B Purchase
Peloso Paul

Chief Medical Officer

Officer
6,000 +inf%
18.00
US$108,000 		6,000 +inf% 18.00 US$108,000
2023-05-11 2023-05-09 B Purchase
3.7
SEIDENBERG BETH C
Non-Executive Director Large shareholder
60,000 +inf%
18.00
US$1,080,000 		60,000 +inf% 18.00 US$1,080,000
2023-05-11 2023-05-09 B Purchase
3.7
SEIDENBERG BETH C
Non-Executive Director Large shareholder
1,250,000 +14.6%
18.00
US$22,500,000 		1,250,000 +14.6% 18.00 US$22,500,000
Explore more

More insider trading research around ACELYRIN Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America